Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

News

Can Decreased Nectin-4 Expression Predict Resistance to Enfortumab Vedotin in Urothelial Carcinoma?

Medical Literature

Can a Novel Approach to Transurethral Resection Reduce Recurrence of Bladder Cancer?

News

Can a Genetic Signature Be Used to Predict Clinical Outcomes in Bladder Cancer?

News

A Novel Tool for Risk Assessment and Personalized Care for Patients With Bladder Cancer

News

Methylation of PENK: Potential Biomarker for Early Detection of Bladder Cancer?

News

Rogaratinib Versus Chemotherapy for Advanced Urothelial Carcinoma: Phase II Trial Results

Medical Literature

Chinese Research Team Identifies Potential Biomarker of Early-Stage Bladder Cancer

Petros Grivas, MD, PhD, on Update on Treatment With Sacituzumab Govitecan-hziy and Pembrolizumab in Urothelial Cancer

Simon J. Crabb, PhD, MBBS, on Rucaparib Following Chemotherapy for Urothelial Carcinoma: Update From the ATLANTIS Trial

View More

Advertisement

JNCCN Spotlights

Adjuvant Nivolumab

Enfortumab Vedotin-ejfv

Sacituzumab Govitecan-hziy

View More

More

News

ASTRO 2022: Can Genetic Mutations Determine Response to Trimodality Therapy in Bladder Cancer?

Risk-Aligned Bladder Cancer Surveillance: Data-Driven Approach to Implementation Mapping

Phase II TALASUR Trial to Study Maintenance Talazoparib Plus Avelumab in Urothelial Carcinoma

Can Single-Port Robotic Surgery Improve Cosmesis After Bladder Procedures?

Is Infection With Human Polyomavirus a Causative Factor in Bladder Cancer in Southern Iran?

ASTRO 2022: Radiotherapy Versus Surgery for Node-Positive, Nonmetastatic Bladder Cancer

Rogaratinib Versus Chemotherapy for Advanced Urothelial Carcinoma: Phase II Trial Results

Can a Genetic Signature Be Used to Predict Clinical Outcomes in Bladder Cancer?

View More

Advertisement

Published

Medical Literature

Newly Developed and Validated Prognostic Signature for Patients With Bladder Cancer

Long Non-Coding RNA: Potential Therapeutic Target in Bladder Cancer?

Is There a Link Between Bladder Cancer and Human Papillomavirus?

Use of Cabozantinib Plus Nivolumab After Immunotherapy in Metastatic Urothelial Carcinoma

View More

Ongoing

CE Activities

Genitourinary Cancers: Assessing the Roles of Immune-Based and Targeted Therapies in a Changing Treatment Landscape

Oncology Today with Dr Neil Love: Management of Nonmetastatic Urothelial Bladder Cancer

Archived Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer

Breakfast with the Investigators: Urothelial Bladder Cancer

View More

Available

Clinical Trials

Evaluating Cystectomy with Perioperative Pembrolizumab and Perioperative Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Tissue and Body Fluid Analysis from Patients with Bladder Cancer and Other Urothelial Cancers of the Urinary Tract

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.